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Plasma Tie2 is a tumor vascular response
biomarker for VEGF inhibitors in metastatic
colorectal cancer
Gordon C. Jayson1, Cong Zhou2, Alison Backen3, Laura Horsley1, Kalena Marti-Marti1, Danielle Shaw4,
Nerissa Mescallado1, Andrew Clamp5, Mark P. Saunders5, Juan W. Valle1, Saifee Mullamitha5, Mike Braun5,
Jurjees Hasan5, Delyth McEntee5, Kathryn Simpson3, Ross A. Little6, Yvonne Watson6, Susan Cheung6,
Caleb Roberts6, Linda Ashcroft5, Prakash Manoharan1, Stefan J. Scherer7, Olivia del Puerto8, Alan Jackson6,
James P.B. O’Connor2, Geoff J.M. Parker6,9 & Caroline Dive3
Oncological use of anti-angiogenic VEGF inhibitors has been limited by the lack of informative
biomarkers. Previously we reported circulating Tie2 as a vascular response biomarker for
bevacizumab-treated ovarian cancer patients. Using advanced MRI and circulating bio-
markers we have extended these ﬁndings in metastatic colorectal cancer (n= 70).
Bevacizumab (10 mg/kg) was administered to elicit a biomarker response, followed by
FOLFOX6-bevacizumab until disease progression. Bevacizumab induced a correlation
between Tie2 and the tumor vascular imaging biomarker, Ktrans (R:−0.21 to 0.47) implying
that Tie2 originated from the tumor vasculature. Tie2 trajectories were independently
associated with pre-treatment tumor vascular characteristics, tumor response, progression
free survival (HR for progression= 3.01, p= 0.00014; median PFS 248 vs. 348 days
p= 0.0008) and the modeling of progressive disease (p < 0.0001), suggesting that
Tie2 should be monitored clinically to optimize VEGF inhibitor use. A vascular response is
deﬁned as a 30% reduction in Tie2; vascular progression as a 40% increase in Tie2 above
the nadir. Tie2 is the ﬁrst, validated, tumor vascular response biomarker for VEGFi.
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Anti-angiogenic VEGF inhibitors (VEGFi) have becomesome of the most widely prescribed drugs in oncology1.Despite intense effort to ﬁnd biomarkers that would
optimize treatment with VEGFi, predictive biomarkers have
proven elusive. However, there have been few attempts identify
and validate response biomarkers. Several trials2,3 have reported
pharmacodynamic changes in a variety of circulating biomarkers
during treatment with VEGFi. The most consistent pharmaco-
dynamic data pertain to the plasma concentration of the angio-
poietin receptor, Tie2. The ﬁndings are of considerable interest as
(i) they are mechanistically plausible given the interaction
between VEGF and Angiopoietin signaling pathways;4,5 (ii)
VEGFi-induced pharmacodynamic changes in Tie2 have been
observed in glioma2, gall bladder6, and colorectal cancer;3 and
(iii) the Ang/Tie2 pathway is a known and valid clinical target in
colorectal7 and ovarian cancer8–10. Despite these important
associations, the clinical signiﬁcance of Tie2 behavior has not
been determined.
Recently, we completed studies in ovarian cancer, which
revealed that Tie2 functions as a vascular response biomarker
in patients treated with the anti-VEGF antibody, bevacizumab,
and cytotoxic therapy11,12. In these studies, we showed that
bevacizumab-induced PD changes in Tie2 were of clinical value.
In particular, progression modeling was signiﬁcantly improved
when Tie2 (the vascular response biomarker) was studied with
CA-125 (the epithelial marker). While these ovarian cancer
studies provided insight into the potential clinical utility of
Tie2 as a vascular biomarker they were based solely on circulating
biomarkers and lacked direct tumor-speciﬁc data that can only
be generated through imaging. Here, we deployed advanced
imaging alongside the circulating biomarkers to qualify, in
metastatic colorectal cancer (mCRC), Tie2 as the ﬁrst, generic,
tumor vascular response biomarker for VEGFi. In addition
the study validates the concept that a cancer consists of
multiple tissue types, in this case the epithelial and vascular
components, which should be considered as targets at each
recurrence of cancer treatment; the multi-tissue compartment
model of cancer therapy.
Results
Seventy patients with mCRC were recruited. Their demographic
and survival statistics are shown in Table 1 and Fig. 1. In all,
nineteen circulating biomarkers and nine imaging biomarkers
were measured (Table 2 and Supplementary Figure 1). The
technical variation of each circulating biomarker was estimated
using technical replicates (Supplementary Figure 2). Most bio-
markers demonstrated technical variation within the range
76–132% (95% CI). Pre-treatment intra-patient variations of
biomarkers demonstrated a range of repeatability values (Sup-
plementary Figure 3).
Pre-treatment biomarker networks are prognostic. The study
investigated a signiﬁcant number of biomarkers. Therefore,
we performed an initial analysis to evaluate the relationship
between all the biomarkers with one another to avoid the con-
founding factor of multiple comparisons while simultaneously
focusing attention on key sets of biomarkers. To do this, we
examined the change in correlative relationships between bio-
markers before and during treatment. Pearson correlation net-
works, as described previously11,12, of the circulating and imaging
biomarkers were generated to determine the presence of positive
or negative correlations (Fig. 2).
Before treatment many circulating biomarkers that relate to
the biology of angiogenesis formed strongly correlated clusters
(median r= 0.40, r ranges from −0.21 to 0.97). This infers
biologically coordinated regulation of the neo-vasculature
(Fig. 2a)12. Imaging biomarkers of vascular function, IAUC60,
Ktrans, vp and Enhancing Fraction (EF) also correlated strongly
with each other (Fig. 2a). However, there was no evidence of
correlations between circulating and imaging biomarkers. This
implies that in treatment-naive patients, the circulating and
imaging biomarkers measured different aspects of tumor neo-
vasculature.
Further, the biomarker of tumor burden, circulating CK1813,14,
which relates to epithelial cell death, and Whole Tumor Volume
(WTV) correlated strongly with one another. However, these
biomarkers did not correlate with biomarkers of the neo-
vasculature (Fig. 2a). This indicates a biological and functional
distinction between biomarker signatures that represent the
epithelial and vascular tissue compartments.
Next, we explored the associations between pre-treatment
clinical and demographic factors and the circulating and imaging
biomarkers. However, the only signiﬁcant association to emerge
from this part of the analysis was between total tumor volume
and performance status (PS, p= 0.0078, chi-squared tests).
Univariate analysis of pre-treatment clinical, circulating and
imaging biomarkers for their association with progression free
survival (PFS) indicated that PS, LDH, VEGF-A, VEGF-R2,
CK18, total tumor volume, IAUC, Ktrans, WTV, ETV, and EF
were potential prognostic biomarkers. To investigate further, we
applied a multivariate Cox proportional hazard regression
analysis supported by a bootstrap resampling approach for
validation. This method examines the stability of the ﬁndings
when different data points are included or excluded from the
analysis. Through this, we identiﬁed performance status, total
tumor volume and the ratio of the plasma concentration of
VEGF-R2 to tumor Ktrans as pre-treatment independent prog-
nostic biomarkers for PFS (Fig. 2b, Table 3). The key ﬁnding was
that patients with higher VEGF-R2 to tumor Ktrans ratios had a
worse PFS.
Table 1 Baseline patient characteristics
N Percentage or range
Total patients 70 100
Male 41 59
Female 29 41
Age (median) 63 years 29–77
ECOG Performance Status 0 38 54
ECOG Performance Status 1 29 41
ECOG Performance Status 2 3 4
Disease site—bowel 58 83
Disease site—liver 58 83
Disease site—lung 25 36
Disease site—lymph nodes 24 34
Disease site—bone 1 1
Disease site—other 10 14
1 metastatic site 31 45
2 metastatic sites 26 37
3+metastatic sites 13 18
Well differentiated tumor 7 10
Moderately differentiated tumor 45 64
Poorly differentiated tumor 9 13
Unknown degree of differentiation 9 13
Primary tumor in situ—yes 22 31
Primary tumor in situ—no 48 69
Platelets (normal range 150–400) 373 172–931 × 109/L
LDH (normal range < 450) 475 157–9335 IU/L
CEA (normal range < 5) 47 <3–16,485 IU/L
CEA carcino-embryonic antigen, ECOG Eastern Cooperative Group, IU international units, LDH
lactate dehydrogenase, L litre
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Fig. 1 Progression-free and overall survival Kaplan–Meier estimator graphs. a Shows the proportion of the 70 eligible patients who are alive and free from
disease-progression; the median PFS was 283 days (9 months; 95% CI 265–351 days or 8.8–11.7 months). One year and 2 year PFS statistics were
31 and 7% respectively. Note; no patient developed PD between days 98 and 182. b Shows the proportion of the 70 eligible patients who are alive; the
median OS was 578 days (19.3 months; 95% CI 477–651 days or 15.9–21.4 months). One and 2-year survival statistics were 76 and 29%, respectively.
The slightly lower OS length are not statistically shorter than other published series, but likely reﬂect the eligibility requirement for at least one metastatic
lesion with a diameter between 3 and 10 cm that rendered the lesion amenable to serial MRI. Solid black lines; progression-free or overall survival, dotted
gray lines; 95% CI, dashed black lines; median values, black crossed; patients whose data was censored. PFS progression-free survival, OS overall survival,
CI conﬁdence interval, MRI magnetic resonance imaging
Table 2 Summary of baseline biomarker levels and changes during treatment
Biomarker type Biomarker
name
Pre-treatment levels
(Median ± SD)
Median change at 14 days with
single agent bevacizumab (%)
Biggest median change
during treatment (%)
Median change at
disease progression (%)
Circulating Ang1 2.5 ± 2.0 × 103 102.9 50.8 50.8
Circulating Ang2 4.9 ± 9.0 × 102 76.1 65.7 72.5
Circulating E-selectin 1.5 ± 0.9 × 104 92.8 86.9 96.4
Circulating FGF2 2.6 ± 13.0 × 102 86.5 46.9 57.5
Circulating HGF 4.2 ± 12.2 × 102 93.1 82.0 95.7
Circulating IL6 1.1 ± 6.7 × 101 104.3 148.3 148.3
Circulating IL8 5.0 ± 9.6 × 10 88.6 71.7 87.1
Circulating KGF 7.3 ± 68.4 × 100 92.3 41.1 106.7
Circulating CK18 1.1 ± 0.6 × 103 91.5 58.1 86.7
Circulating PDGFbb 2.4 ± 2.2 × 102 97.2 70.6 82.5
Circulating PLGF 3.3 ± 41.0 × 101 104.1 92.9 113.3
Circulating SDF1b 1.8 ± 1.2 × 103 103.6 114.1 101.3
Circulating Tie2 1.4 ± 0.8 × 104 84.4 80.8 84.8
Circulating VCAM1 5.6 ± 1.9 × 105 103.6 186.3 183.6
Circulating VEGFA 1.9 ± 1.9 × 102 74.8 56.7 62.0
Circulating VEGFC 5.8 ± 10.0 × 102 94.8 64.6 81.4
Circulating VEGFD 5.6 ± 255.3 × 102 100.9 87.9 94.2
Circulating VEGFR1 6.2 ± 78.7 × 101 96.0 91.6 115.7
Circulating VEGFR2 1.1 ± 0.7 × 104 97.6 84.0 84.0
Imaging ADC 1.0 ± 0.2 × 10−3 102.4 91.0 98.8
Imaging EF 9.7 ± 0.5 × 101 96.8 95.9 97.1
Imaging ETV 3.8 ± 12.8 × 104 84.4 43.6 48.3
Imaging WTV 3.9 ± 13.9 × 104 89.6 39.9 61.1
Imaging IAUC 1.7 ± 0.7 × 101 72.1 68.0 72.9
Imaging Ktrans 1.7 ± 1.1 × 10−1 71.7 66.5 74.1
Imaging T1 1.1 ± 0.2 × 103 94.0 86.8 90.4
Imaging Ve 3.1 ± 1.1 × 10−1 88.7 86.5 86.5
Imaging Vp 1.7 ± 1.6 × 10−2 67.8 63.4 63.4
Median pre-treatment levels of circulating and imaging biomarkers are shown, with the standard deviation (SD). Changes through treatment at three time-points are shown, related as a relative
percentage (%) to the pre-treatment baseline levels. Values above 100 indicate increased biomarker levels while values below 100 indicate reduced biomarker levels. Plots of biomarker changes are
shown in Supplementary Figure 2
The units for circulating biomarkers are pg/ml. The units of ADC are mm2/s; ETV and WTV mm3; IAUC s.mmol/l; Ktrans 1/min; T1 ms. EF, Ve and Vp are all ratios and therefore are unit-less, ±
indicates plus and minus around one standard deviation (SD)
Ang1 and 2 angiopoietin 1 and 2, FGFb ﬁbroblast growth factor beta, HGF hepatocyte growth factor, IL6 and 8 interleukins 6 and 8, KGF keratinocyte growth factor, CK18 cytokeratin 18, PDGFbb platelet-
derived growth factor bb isoform, PlGF placental growth factor, SDF1b stromal-derived growth factor beta, VCAM1 vascular cell adhesion molecule 1, VEGFA, C, D, R1, and R2 vascular endothelial growth
factor A, C, and D and receptors 1 and 2, ADC apparent diffusion coefﬁcient, EF ejection fraction, ETV enhancing tumor volume, WTV whole tumor volume, IAUC initial area under the contrast agent
concentration curve, Ktrans endothelial transfer constant, Ve extracellular extravascular space fractional volume, Vp plasma fractional volume
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Bevacizumab induces correlation of Ang2, Tie2, and Ktrans.
Following treatment with single agent bevacizumab, the strong
correlations seen between many circulating biomarkers were
weakened (median reduction of r= 0.15, r ranges from −0.22 to
0.70). This disruption of the core network relationships of cir-
culating biomarkers (Fig. 2c) implied that bevacizumab impacted
speciﬁc aspects of the tumor neo-vasculature. The relationships of
imaging biomarkers to one another were essentially unchanged
during this period (Fig. 2c).
The most signiﬁcant change observed was development of a
correlative relationship between Ang2, Tie2, and tumor Ktrans,
where the correlation between circulating Tie2 and tumor Ktrans
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emerged and increased from −0.21 pre-treatment to 0.47
following treatment. This ﬁnding suggested that Tie2 was a
biomarker closely related to tumor vasculature. The correlation
between Tie2 and Ang2 was also strengthened, corroborating our
previous ﬁndings of increased bevacizumab-induced correlation
in the Ang/Tie pathway, in ovarian cancer12.
Finally, we evaluated the effect of subsequent addition of
cytotoxic chemotherapy to bevacizumab on the network of
biomarkers of the neo-vasculature. Cytotoxic chemotherapy did
not signiﬁcantly impact further on any correlations, within the
circulating biomarkers alone, within the imaging biomarkers
alone, or between the circulating and imaging biomarkers
(Supplementary Figure 4).
Our attention had already been directed towards Tie2 as we
had previously reported in ovarian cancer that bevacizumab
induced a correlation between Angiopoietins (Ang) and Tie2 and
that Tie2 was of clinical signiﬁcance in the disease11,12. The data
presented here validate this ﬁnding in colorectal cancer, where the
bevacizumab-associated biomarker signature not only includes
Ang2 and Tie2 but also importantly revealed that bevacizumab
induced a correlative relationship between Tie2 and the tumor
vascular imaging parameter Ktrans (Fig. 2c). Taken with other
reports of PD changes in Tie2 induced by VEGFi, the implication
is that Tie2 is a pan-tumor PD biomarker for antibody and small
molecule VEGF inhibitors. Further, through analysis of the pre-
treatment values of biomarkers (Table 2) and their changes
during treatment (Supplementary Figure 1a–c), we have here
deﬁned a bevacizumab-induced vascular response as a greater
than 30% reduction in Tie2 concentration since this exceeded the
95% conﬁdence intervals of treatment-free variations in Tie2.
The Tie2 signature is derived from tumor vasculature. Corre-
lative studies, performed to avoid the confounder of multiple
comparisons, revealed in ovarian cancer12 and in this study in
colorectal cancer an induced relationship between Tie2 and its
ligands in patients’ plasma samples. Here, in colorectal cancer,
network (Fig. 2) and biomarker data (Supplementary Figure 1
and Table 2) revealed that bevacizumab induced correlations
between Ang2, Tie2, and Ktrans, the imaging parameter most
frequently employed in studies of VEGF inhibitors15, which is a
composite of endothelial surface area and vascular permeability.
Since the Ang2–Tie2 pathway has been implicated in vessel
destabilization16 the reductions in value and coordination of these
parameters observed here potentially reﬂect vascular normal-
ization17, can be detected through changes in Ktrans8.
We extended the evaluation from the correlative two time
point analysis presented above to a more extensive and dynamic
analysis of Tie2, tumor Ktrans and the epithelial biomarker, CK18.
Here we used an unsupervised hierarchical clustering analysis to
avoid arbitrary classiﬁcation of patients into early and late
responders. This analysis separated patients into two distinct
cohorts with different Tie2 trajectories (Fig. 3a, p= 1.8 × 10−6,
Mann–Whitney U test). Taking the same cluster-deﬁned popula-
tions, we plotted the trajectories of tumor Ktrans (Fig. 3b, p=
0.003, Mann–Whitney U test) and CK18 (Fig. 3c, p= 0.18,
Mann–Whitney U test) showing that the cluster-deﬁned behavior
of Tie2 (Fig. 3a) closely resembled tumor Ktrans (Fig. 3b) but not
that of CK18 (Fig. 3c). Thus, as bevacizumab induced a
correlation between Ktrans and Tie2 shortly after treatment
started and the trajectories of the two Tie2 clusters mirrored
changes in tumor Ktrans but not CK18, the data imply that Tie2
reﬂects bevacizumab-induced tumor vascular modulation. This is
important as our data11,12 and the PD data of others2,3,6 had
suggested that the Tie2 change was of vascular origin. Here, the
imaging data imply that the Tie2 signal originates from tumor
vasculature or at least through a tumor vasculature-associated
Fig. 2 Correlation networks of circulating and imaging biomarkers. a Pearson’s correlation networks were constructed for circulating and imaging
biomarkers measured at baseline. Clusters with median correlation coefﬁcients above 0.5 are shown in thick black lines, while <0.5 but ≥ 0.35 are shown
with dotted lines and correlations <0.35 are not displayed. b Compares PFS outcomes in two groups of patients deﬁned by the ratio of pre-treatment
VEGFR2:Ktrans, where the cut-off was selected as the 33rd percentile of the ratios. Thus 24 patients were included in the worse prognostic group
(dashed black line) and 46 in the better prognostic group (solid black line). The median survival intervals of the two groups were 248 (range 58–423) and
348 (73–1750) days (p= 0.0008, Log rank test), respectively. Prognostic factors such as performance status and tumor volume were controlled for by
using Cox proportional hazard analysis. The hazard ratio demonstrated that patients with high VEGFR2:Ktrans ratio have a signiﬁcantly greater risk of
progression than the other cohorts (HR 3.01, p= 0.00014, Wald test). This deﬁnes this cohort as the poor prognostic group, we compared the group’s
WTV derived from DCE-MRI data with that of the other patient groups. c Pearson’s correlation networks were constructed for circulating and imaging
biomarkers measured after two weeks of treatment with bevacizumab; tight correlations between circulating biomarkers were lost and some biomarkers
were completely removed from the correlative relationship (arrows). In contrast bevacizumab induced a correlative relationship between Ktrans, Ang2, and
Tie2 (gray line). Clusters with median correlation coefﬁcients above 0.5 are shown in thick black lines, while <0.5 but ≥ 0.35 are shown with dotted lines
and correlations <0.35 are not displayed. Ang1 and 2, angiopoietin 1 and 2; FGFb, ﬁbroblast growth factor beta; HGF, hepatocyte growth factor, IL6 and 8,
interleukins 6 and 8; KGF; keratinocyte growth factor, CK18; cytokeratin 18, PDGFbb; platelet-derived growth factor bb isoform, PlGF; placental growth
factor, SDF1b; stromal-derived growth factor beta, VCAM1; vascular cell adhesion molecule 1; VEGFA, C, D, R1 and R2; vascular endothelial growth factor A,
C and D and receptors 1 and 2, ADC; apparent diffusion coefﬁcient, EF; ejection fraction, ETV; enhancing tumor volume, WTV; whole tumor volume, IAUC;
initial area under the contrast agent concentration curve; Ktrans; endothelial transfer constant, Ve; extracellular extravascular space fractional volume, Vp;
plasma fractional volume, DCE-MRI; dynamic contrast-enhanced magnetic resonance imaging
Table 3 Univariate analysis of biomarkers before treatment
Parameter p-value
Total tumor volumea 0.0001
WVTb 0.004
EVTb 0.004
EF 0.004
LDH 0.005
ECOG performance status 0.006
VEGFA 0.008
IAUC 0.012
Ktrans 0.017
Cytokeratin18 0.13
VEGFR2 0.19
Clinical, circulating and imaging biomarkers were analyzed using univariate Cox proportional
hazard regression analysis to examine their prognostic signiﬁcance with respect to progression-
free survival. Biomarkers with univariate p-values that were less than 0.05 (listed in this table)
were included in the subsequent multi-variate analysis (Table 4)
aTotal tumor volume calculated from CT scan
bWTV and ETV calculated from MRI scan
EF ejection fraction, ETV enhancing tumor volume, WTV whole tumor volume, LDH lactose
dehydrogenase, ECOG Eastern Cooperative Group, VEGFA and R2 vascular endothelial growth
factor A and receptor 2, IAUC initial area under the contrast agent concentration curve; Ktrans
endothelial transfer constant, MRI magnetic resonance imaging
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cell lineage. This ﬁnding is consistent with the known data
documenting expression of Tie2 in vessels18 and its modulation
by VEGF4,5.
Prolonged reductions in Tie2 are associated with better PFS.
Our data11,12 and those of others2,3,6 demonstrate that Tie2 is
a pan-tumor, vascular PD biomarker for VEGF inhibitors. As the
Ang2–Tie2 pathway is heavily implicated in mediating16,18,19
angiogenesis, we hypothesized that those patients who had the
greatest and most prolonged VEGFi-induced reductions in
Tie2 should have fared the best and vice versa.
As a ﬁrst step in the analysis of the prognostic signiﬁcance of
Tie2 we tested the association between the two groups of patients
deﬁned in the unsupervised clustering analysis of Tie2 (Fig. 3a)
and the pre-treatment clinical and biomarker parameters that
had been identiﬁed as having independent prognostic signiﬁcance
(the VEGF-R2 to Ktrans ratio; ﬁrst section of results). While the
Tie2 curves (Fig. 3a) were not associated with pre-treatment
clinical prognostic factors, there was a signiﬁcant association with
VEGF-R2 to Ktrans ratio (p= 0.014, Fisher’s exact test, Supple-
mentary Table 1) in which patients with the higher ratio
manifested less reduction in Tie2. Thus, there is a group of
patients, who are deﬁned by a high VEGF-R2/Ktrans ratio and less
signiﬁcant and durable reductions in Tie2, who have a shorter
PFS (Fig. 2b: median PFS 248 vs. 348 days, p= 0.0008, Log rank
test. HR for progression: 3.01, p= 0.00014, Wald test). As VEGF-
R2 is most likely derived from the endothelial bed reﬂecting
the volume of tumor microvasculature and tumor Ktrans and the
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Fig. 3 Changes in Tie2 but not CK18 reﬂect tumor vascular control (Ktrans). Two cohorts (or clusters) of patients were identiﬁed through an unsupervised
hierarchical clustering of Tie2 trajectories (a). In one cohort, there was an immediate but transient reduction (dotted line) in Tie2, while in the other cohort
there was a later but more sustained reduction (solid line). The two cohorts behaved signiﬁcantly differently (P= 1.8 × 10−6, Mann–Whitney U test).
Similar cohorts of patients were identiﬁed with Ktrans values (b), which again behaved signiﬁcantly differently (P= 0.003, Mann–Whitney U test). The
pattern of behavior of CK18 was different (c), and the two cohorts were not signiﬁcantly different (P= 0.18, Mann–Whitney U test). This indicates that
Tie2 reﬂects the impact of bevacizumab on tumor vasculature. Error bars indicate the standard error. d Shows an example of Ktrans parameter maps, which
reﬂect the tumor behavior of the two cohorts, shown in b. The largest difference in parameter maps can be seen in the two middle position maps,
which correspond to the maximum difference between the two cluster-derived curves. CK18; cytokeratin 18, Ktrans; endothelial transfer constant
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Ang/Tie2 axis are biomarkers that reﬂect the sensitivity of the
tumor to VEGF inhibitors, the implication is that the worst
prognostic group bears tumors that achieve angiogenesis through
a non-VEGF dependent pathway.
Having deﬁned better and worse prognostic groups, we
evaluated the tumor volumetric response to bevacizumab in each
group. WTV did not change in the poor prognosis group but was
signiﬁcantly reduced in the better prognosis patients (p= 0.029,
Mann–Whitney U test, Fig. 4a). These differences were apparent
within 4 days of bevacizumab monotherapy. By the end of a
two-week cycle of bevacizumab patients with beneﬁcial outcome
had attained a median reduction in WTV to 82% of pre-
treatment levels (95% CI: 47–143%). We then analyzed the tumor
volumetric change against the percentage time that elapsed
between randomization and the date of progression/censoring
(%PFS). This analysis demonstrated that a signiﬁcant difference
in tumor response remained throughout the clinical course
of combination therapy with bevacizumab and cytotoxic
chemotherapy (p= 0.012, Mann–Whitney U test, Fig. 4b).
Taking these data together, we have identiﬁed a group of patients
with signiﬁcantly worse PFS. The patients’ tumors were characterized
by high VEGF-R2 to Ktrans ratio before treatment, by a lack of tumor
size reduction after two weeks’ single dose of bevacizumab and by
transient bevacizumab-induced vascular control that was reﬂected
by less profound and less durable reductions in Tie2. The data
imply that patients in the poor prognosis group had tumors that
were less dependent on VEGF signaling.
Validation of the multi-tissue compartment model of cancer.
Our previous ovarian cancer studies11,12 provided the biomarker
data to suggest that the vascular and epithelial compartments
were additive targets for anti-cancer treatment. Therefore, we
investigated the colorectal cancer data for the same relationship
as, in conjunction with clinical trial data7,20–24, such a model
would suggest that the tumor vascular and epithelial tissue
compartments should be targeted at each clinical recurrence of
angio-sensitive cancers that are usually treated with cytotoxic
chemotherapy and VEGFi.
The data showed that bevacizumab imposed an association
between Tie2, Ang2, and tumor Ktrans and that the impact on
Tie2 reﬂected vascular changes in tumor, volumetric response,
and PFS. We then determined whether changes in the epithelial
and vascular compartments were independent of each other. The
analysis is based on the identiﬁcation of an inﬂection point in
biomarker data where, for instance, a parameter such as Tie2 has
been decreasing over time and then starts to increase. This
Bayesian hierarchical modeling approach allows evaluation of
different mathematical rules for the calculation of the inﬂection
point, which is considered to infer a change in biology. In the case
of Tie2 an inﬂection point suggests vascular progression, whereas
in the case of CK18 an inﬂection point suggests epithelial
progression. The approach also generates putative rules that could
subsequently be used for clinical decision making.
Based on these biomarker-deﬁned response and progression
rules, tumor progression predicted by circulating CK18 and
Tie2 was summarized to identify the behavior of the level of the
entire cohort. Critically, the performance of predictions made
from actual data derived from the two biomarkers (66%) was
superior to the performance of either biomarker alone; 54 and
41%, respectively Fig. 5a).
In a complex clinical dataset there is often some missing data.
The Bayesian hierarchical modeling approach allows interpola-
tion to simulate missing data and provide a “full” dataset.
Simulated data demonstrated that the combined biomarkers
were capable of predicting progression in 77% of patients,
which exceeded the result from actual data that had some missing
data points. Once again, this ﬁnding showed that prediction of
outcome from combined Tie2 and CK18 biomarkers provided
better performance compared to either biomarker alone (p <
0.0001, Mann–Whitney U test). Further, we found evidence of
temporal disconnect between the timing of progression in the
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Fig. 4 Prognostic value of angiogenic biomarkers. The association between a less profound reduction in Tie2 and higher Ktrans:VEGFR2 ratio (Fig. 2b)
identiﬁed a poor prognostic group. The WTV derived from DCI-MRI of this poor prognostic group (dotted lines) was compared with better prognostic
outcome group (solid lines). a Shows the differential impact of single agent bevacizumab (10mg/kg) on WTV between the two groups up to 15 days after
treatment, with effects emerging by day 4 (P= 0.029, Mann–Whitney U test). b Volumetric analysis showed persistence of this difference throughout the
course of combined cytotoxic chemotherapy and bevacizumab, with changes in WTV plotted using the same groups against the percentage time that
elapsed between randomization and the date of progression/censoring (%PFS; P= 0.012, Mann–Whitney U test). Error bars indicate the standard error.
WTV; whole tumor volume, DCE-MRI; dynamic contrast-enhanced magnetic resonance imaging, VEGFR2; vascular endothelial growth factor receptor 2,
PFS; progression-free survival
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vascular and the epithelial compartments. Across the entire
cohort, Tie2 predicted progression before CK18 with an average
lead-time of 50 days (p= 0.026, Mann–Whitney U test).
In all, these data suggest that RECIST-deﬁned PD can best be
anticipated through a combination of multimodal biomarkers
that reﬂect both vascular progression and epithelial progression.
Thus, epithelial and vascular biomarker data improve the
modeling of progressive disease when considered together,
supporting the hypothesis that the two tissue compartments
may be valid targets at treatment for initial presentation and re-
treatment in patients with disease relapse (Fig. 6a).
Using Tie2 to deﬁne vascular response and progression. Esti-
mates of pre-treatment intra-patient variation indicated that the
95% CI of Tie2 and CK18 were 0.53 and 0.42 respectively
(log2 scale, Supplementary Figure 3). Thus, a Tie2-deﬁned vas-
cular response can be inferred when its plasma concentration is
reduced by at least 30% during the ﬁrst 3 cycles of treatment. A
CK18 reported epithelial response can be inferred when its
plasma concentration is reduced by at least 25% over this time
frame. The Bayesian hierarchical modeling approach revealed
that a 50 and 40% increase above the nadir concentrations of
plasma CK18 and Tie2, respectively, were indicative of disease
progression (Fig. 6b–e; Supplementary Figure 5).
Looking at the individual patient data (Fig. 6b–e), it becomes
clear that some patients develop tissue compartment progression
in vascular, epithelial or both compartments by the point of
conventional RECIST-deﬁned disease progression. The advance
that Tie2 brings is that a VEGFi can be stopped much earlier than
conventional management would dictate, if there is no Tie2
deﬁned response or if Tie2 reported progression occurs. On the
other hand an epithelial biomarker progression deﬁned through
increases in CK18 can sometimes precede Tie2-deﬁned vascular
biomarker progression. Such patients may beneﬁt from continued
VEGFi beyond RECIST progression as they may experience
signiﬁcantly decelerated tumor growth that persists until Tie2-
deﬁned vascular biomarker progression occurs.
Discussion
Anti-angiogenic VEGFi are widely prescribed in oncology
yet their effective use has been compromised by the lack of
biomarkers to optimize their clinical utility. Here, we have
studied a panel of 19 circulating and 9 imaging biomarkers in
70 patients with metastatic colorectal cancer during treatment
with bevacizumab followed by cytotoxic chemotherapy and
bevacizumab. The data were analyzed using an unsupervised
statistical approach to avoid the confounder of multiple com-
parisons and to avoid arbitrary classiﬁcation of biomarker
patterns. While changes in other biomarkers occurred and are
of potential interest, our attention was drawn to Tie2 because
single agent bevacizumab induced a correlation between Ang2,
Tie2, and Ktrans, whereas the relationship between several other
biomarkers was unchanged or weakened.
This approach allowed us to demonstrate that Tie2 is a
tumor vascular response biomarker for bevacizumab in patients
with metastatic colorectal cancer. The imaging data demonstrate
that in solid tumors the Tie2 biomarker signal is derived
from tumor vasculature and that it is of clinical signiﬁcance.
As we have now demonstrated the value of circulating Tie2 in
ovarian11,12 and colorectal cancers, when treating patients with
bevacizumab-cytotoxic chemotherapy combinations and others
have described similar ﬁndings in colorectal cancer3, glioma2
and gall bladder6 cancer in trials of the VEGF RTKi, cediranib,
it is credible that Tie2 is a generic circulating tumor vascular
response biomarker for VEGF inhibitors. Our conﬁdence in
Tie2 as a generic response biomarker for VEGF inhibitors is
thereby enhanced by these ﬁndings in four tumors types, using
two different classes of VEGF inhibitor in at least two different
laboratories2,3.
Our ﬁndings also provide some key data to support
clinical translation of the Tie2 assay. The small intra-patient
variation in pre-treatment concentrations of Tie2 provides
evidence of assay precision increasing conﬁdence in the
potential clinical utility of this biomarker. Further, we have
shown that a vascular response can be deﬁned as a conﬁrmed
reduction in Tie2 concentrations of more than 30% while
the biochemical deﬁnition of vascular progression is a greater
than 40% increase in plasma Tie2 concentrations above the
nadir. The suitability of these criteria to inform clinical decisions
can now be tested formally in independent datasets to
help develop guidelines for interpreting a clinically approved
Tie2 assay.
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Fig. 5 Predicting disease progression using plasma CK18 and Tie2 levels. The ﬁgure shows the potential of Tie2, cytokeratin 18 (CK18), and both
biomarkers modeled together to predict disease progression. The prediction made by CK18 alone is shown in light gray, by Tie2 alone is shown in mid-gray
and using the combination of CK18 and Tie2 in black. a Shows predictions based on actual data where the combined biomarkers predicted progression in
66% of patients, whereas single biomarker predictions of progressive disease were achieved in 54 and 41%. Interestingly the prediction derived from CK18
occurred later than that from Tie2 with a lead-time of 50 days (14% PFS) as the increase in the Tie2 biomarker predates that of CK18. b Shows the same
calculation but using simulations to ﬁll any missing data. Again a signiﬁcant improvement on the number of predictions was observed when Tie2 and CK18
were used jointly for prediction (p < 0.0001, Mann–Whitney U compared with either single antigen), revealing clear evidence of additivity between the two
biomarkers with respect to predicting progressive disease. Error bars indicate the standard error. CK18; cytokeratin 18, PFS; progression-free survival
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Accepting the clinical value of Tie2, the next question is whe-
ther Tie2-deﬁned vascular progression reﬂects a functional role of
Ang2/Tie2 in mediating resistance to VEGF inhibitors4. This is
critical as, while we know that single agent Ang/Tie2 inhibitors are
clinically active8, most phase III trials of Ang/Tie2 inhibitors have
not selected patients on the basis of biomarkers and the results to
date have only been modestly positive10. Biomarker-directed trials
could test this hypothesis. Several mechanisms of resistance to
VEGFi have been described25 and studies have suggested that
acquired resistance to VEGF inhibitors might be mediated by
macrophages26–28. Thus an alternative hypothesis about the
putative role of the Ang-Tie2 axis in effecting resistance to VEGFi,
is that acquired resistance to VEGFi is mediated through Tie2-
expressing or -modulated monocytes/macrophages. This alter-
native hypothesis is consistent with our observed correlation
between Ang2 and Tie2, which might reﬂect local Ang2-mediated
recruitment of Tie2-expressing macrophages at the point of vas-
cular progression29. Further, a recent publication has shown that
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macrophage-mediated resistance to VEGFi could be reversed by
administration of inhibitors of macrophage CSF-1 receptors30,
in vivo, potentially highlighting a strategy to overcome resistance
to VEGFi, when Tie2 increases. To some extent questions over the
functional roles of different cell types in mediating VEGFi resis-
tance will only be answered through detailed and warranted stu-
dies of serial tumor biopsies.
Our study, taken in conjunction with others cited above, sug-
gests that Tie2 is a generic VEGFi response biomarker, but some
caveats should be acknowledged. The mechanisms responsible
for the changes in Tie2 have not been deﬁned at the microscopic
level although this should not detract from the potential clinical
utility of the biomarker in view of the macroscopic evidence
derived from advanced imaging. To date only a few hundred
patients have provided samples for these assays and these patients
have all been recruited from within clinical trials that evaluated
multiple potential biomarkers simultaneously. Real world eva-
luation in larger populations is now required to deﬁne the clinical
value of the assay. Further, while we have deﬁned a vascular
response as a greater than 30% reduction in Tie2, the duration
over which this should be studied is not clear although existing
data suggest that such an effect should be seen within 9 weeks of
starting treatment.
Randomized trials in the ﬁrst-line, second-line, and third-line
colorectal/ platinum-resistant ovarian cancer settings7,20–24,31
show that the addition of VEGF pathway inhibitors to cytotoxic
therapy improves PFS1. The question is how to use the infor-
mation derived here to improve use of VEGF inhibitors and
thereby translate these improvements in PFS into improved OS.
In this study we have demonstrated the independent and additive
value of modeling both epithelial and vascular compartments in
cancer patients. The clinical trial results and our now validated
model emphasize the critical importance of considering the vas-
culature as a target for re-treatment with anti-angiogenic agents
in patients previously treated with such drugs. Rather than
restricting anti-angiogenic agents to initial presentation, these
agents should be instituted and maintained in angio-sensitive
tumors until Tie2-deﬁned vascular progression at each episode of
progressive disease.
Extrapolating further, a “multi-compartment” model of cancer
care may in due course encompass the many other phenotypic
compartments that represent the “hallmarks of cancer”, which
were described by Hanahan and Weinberg32, including activation
of invasion and metastasis and avoidance of immune destruction.
Thus, in the same way that our data suggest that use and re-use of
VEGFi should be considered at each recurrence of angio-sensitive
cancer using Tie2 to guide therapy, so in time the same principles
might also apply to immunotherapies throughout patients’ lives
with cancer.
Methods
Clinical trial. This study was granted approval from the National Research
Ethics Service, Central Manchester Research Ethics Committee on 15 June
2009 (REC Reference 09/H1008/99). The study was registered with EudraCT
(number 2009-011377-33). The study was performed in adherence with the
relevant ethical guidelines and all patients granted written informed consent
prior to enrollment in this study. In this prospective trial seventy patients with a
new diagnosis of metastatic colorectal cancer, whose tumors were amenable to
advanced imaging, were treated with bevacizumab 10 mg/kg to deﬁne a drug
speciﬁc biomarker signature followed, two weeks later, by FOLFOX-6 or
XELOX with bevacizumab at a dose intensity of 2.5 mg/kg/week until progressive
disease occurred; the primary endpoint. All patients received bevacizumab at a
dose intensity of 2.5 mg/kg/week along with combined oxaliplatin and a ﬂuor-
opyrimidine (5-ﬂuorouracil, 5FU), a version of FOLFOX-6 based on the
NO16966 trial regimen33. Brieﬂy, for patients with a central venous catheter,
oxaliplatin 85 mg/m2, folinic acid 175 mg, and bevacizumab 5mg/kg were
administered as short infusions. Then bolus 5FU 400 mg/m2 was administered
and followed by 5FU 2400 mg/m2 over 46 h. This was administered on a 2-weekly
schedule. For patients who did not have a central venous catheter, oxaliplatin
130 mg/m2, and bevacizumab 7.5 mg/kg were administered intravenously every
3 weeks with oral capecitabine 1000 mg/m2 bd for 14 of every 21 days. Dose
modiﬁcations were made in accordance with local protocols for Common
Toxicity Criteria for Adverse Events (CTC AE) grade 3 or 4 toxicities. Tumors
were radiologically evaluated every 12 weeks according to RECIST 1.0. If
oxaliplatin was withdrawn for toxicity, patients could continue treatment with
5FU and bevacizumab. Patients were recruited between 2009 and 2012 and
followed up until 2016.
Eligible patients had a performance status of 0–2, were aged 18 years or
more, and had a life expectancy of 12 or more weeks. Adequate bone marrow,
hepatic and renal function including proteinuria <2+ on urine dipstick, were
required. The INR and APTT were a maximum of 1.5 fold the upper limit of
normal. Eligible patients had to have disease that was measureable (3 cm or
more) and amenable to diffusion-weighted MRI (DW-MRI) and dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI). Imaging focused on liver
metastases that were between 3 and 10 cm diameter. Exclusion criteria included
previous treatment for metastatic disease (adjuvant therapy at least 12 months
earlier was permitted), brain metastases, spinal cord compression, uncontrolled
inter-current illness, pregnant or breast-feeding women and surgery, signiﬁcant
injury or radiotherapy in the 4 weeks prior to ﬁrst treatment. Previous
treatment with VEGF pathway inhibitors was not permitted and hypertensive
patients were excluded. Patients with clinically signiﬁcant cardiovascular disease
or thrombo-embolism within the previous 6 months were excluded. Patients
with hemorrhagic diathesis, those receiving aspirin at 325 mg/day or more and
those who had started therapeutic anti-coagulation within the previous 4 weeks
were ineligible. Additional exclusion criteria included another malignancy
within the previous 5 years, dihydro-pyrimidine dehydrogenase deﬁciency, non-
healing wound/fracture, pre-existing grade 2 neuropathy, and uncontrolled
bowel disorders.
The study (EudraCT 2009-011377-33) was sponsored by The Christie NHS
Trust and ethical approval was given by the NHS Health Research Authority
National Research Ethics Service, North West Greater Manchester Central ethics
committee (reference 09/H1008/99). All patients provided written informed
consent.
Biomarkers. Patients underwent two pre-treatment scans, for DW-MRI and DCE-
MRI within the two weeks before the ﬁrst administration of bevacizumab. At the
same time, two 6 ml blood samples were drawn to quantify pre-treatment plasma
concentrations of circulating biomarkers. These samples were used to establish the
repeatability of imaging and circulating biomarker data and to generate the 95%
conﬁdence intervals that would deﬁne whether treatment induced a statistically
signiﬁcant effect on each biomarker34.
A ﬁrst dose of bevacizumab 10 mg/kg was administered on day 1 and further
imaging and circulating biomarker samples were collected on days 3, 8 (imaging
only), and 15, as guided by our previous work35 (Table S2). On day 15, after
biomarker collection, the oxaliplatin-ﬂuoropyrimidine cytotoxic therapy was
initiated and further imaging and circulating biomarkers were collected on day 22
(7 days into the ﬁrst cycle of bevacizumab combined cytotoxic therapy), at week 6,
at 6 months and at disease progression.
All biomarker studies were carried out by staff that were blinded to the clinical
demographic and outcome data. DW-MRI and DCE-MRI were performed and
plasma samples aspirated before and during treatment up to the point that
progressive disease was diagnosed (Table S1). The biomarker schedule and
methods are described in Supplementary Methods 1.
Circulating biomarkers. Blood samples for measurement of angiogenesis
associated analytes were drawn directly into 6-ml ethylenediaminetetraacetic acid
(EDTA) vacutainers and plasma was separated by centrifugation at 3000× g for
10 minutes. Plasma was immediately aspirated, separated into aliquots and frozen
at a maximum of −20 °C immediately and −80 °C in the laboratory. Samples
were only thawed once for each analysis, which was performed in triplicate.
Enzyme-Linked Immuno-Sorbent Assays (ELISAs) were performed using Search-
Light chemiluminescent arrays and SearchLight Plus charged couple device ima-
ging system (Aushon Biosystems, Boston, US). These multiplex assays allowed
quantiﬁcation of up to six different proteins in each well of a ninety-six well
plate. All assays were performed in the Clinical and Experimental Pharmacology
Group laboratories, Cancer Research UK Manchester Institute to Good Clinical
Practice (GCP) standard and underwent in-house validation as previously
described36. Protein concentrations were assessed using six-plex ELISAs of
Ang2, FGFb, HGF, PDGFbb, VEGF-A and VEGF-C and IL6, IL8, KGF, PlGF,
VEGF-R1, VEGF-R2; duplexes of Ang1 and Tie2 and E-selectin and VCAM-1
and single plexes of VEGFD and SDF1β. The M65 ELISA for cytokeratin 18,
(Peviva, Bromma, Sweden), was used to quantify total epithelial cell
death37shown previously to be a biomarker of tumor burden in colorectal cancer13.
The biomarkers generally follow log-normal distribution (Supplementary Figure 1).
Therefore their longitudinal changes were investigated in log2 scale to reduce
biomarker variation inherent in patients. Technical variations and pre-treatment
intra-patient variation of these proteins were estimated based on log2 transformed
ratios of two technical replicate measurements or two consecutive pre-treatment
measurements.
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Imaging biomarker acquisition and analysis. DW-MRI and DCE-MRI were
performed in one scanning session. All imaging acquisition and analysis was
performed in the Quantitative Biomedical Imaging laboratory, University of
Manchester, to Good Clinical Practice (GCP) standards. Data were acquired
on a 1.5 T Philips Achieva scanner (Philips Healthcare, Best, The Netherlands).
DW-MRI images were acquired using a non-breath holding, fat-suppressed,
spin echo, echo planar imaging sequence with the following parameters: FOV
375 mm × 375 mm; slice thickness 4 mm; number of slices 25; matrix 256 × 256; in-
plane resolution 1.46 mm × 1.46 mm; TR 3416 ms; TE 90ms with diffusion
sensitization (b values) of 0, 150, 500 and 800 s/mm2. MRI protocol was carried
out as previously described and included a turbo spin-echo T1-weighted
sequence; T2-weighted turbo spin-echo sequence and a 3-D DCE-MRI protocol
using an RF-spoiled fast ﬁeld echo (T1-FFE) sequence38. During the dynamic
sequence, 0.1 mmol/kg of gadoterate meglumine contrast agent (Dotarem,
Guebert, France) was administered intravenously at the sixth dynamic time-point
at a rate of 3 ml/s, using a Medrad Spectris power injector (Bayer Healthcare
Pharmaceuticals, USA).
DCE-MRI data were analyzed using in-house software, Manchester
Dynamic Modeling (MaDyM, Manchester, UK). Regions of interest (ROIs)
were deﬁned manually for the whole tumor volume using Java Image software
(JIM version 5.0, Xinpase Systems Ltd, UK) and with reference to the T1- and T2-
weighted images, as well as the DCE-MRI images. The arterial input function
(AIF) was determined for each patient visit using an automated technique
applied to the nearest feeding artery39 and corrected for patient hematocrit. The
individual patient pre-treatment hematocrit readings were used. Parameters
that were reported included whole tumor volume, enhancing volume, enhancing
fraction, tumor median values of the initial area under the contrast agent
concentration curve over the ﬁrst 60 seconds (IAUC6040), and the endothelial
transfer coefﬁcient (Ktrans), plasma fractional volume (vp), and extracellular
extravascular space fractional volume (ve), as derived using the extended Kety
model41, and tumor pre-contrast longitudinal relaxation time T1. DW-MRI was
analyzed by ﬁtting the data to obtain the water apparent diffusion coefﬁcient
(ADC). Voxel-wise estimates of ADC in each ROI were calculated by voxel-
wise ﬁtting of the diffusion weighted image data using S bð Þ ¼ S0 ´ eb ´ADC.
ADC maps were generated and median tumor ADC was calculated to summarize
each tumor.
Statistical design and analysis. The study plan was to recruit 70 evaluable
patients on the grounds that, based on data accrued a year after the 70th and last
patient had entered the study (90% event rate), analysis of the biomarker data
would have an 80% power to detect biomarker stratiﬁed groups with a hazard ratio
of at least 2 in progression free survival, using a Cox proportional hazard regression
analysis at a 5% signiﬁcance level.
Network analysis of all biomarkers was performed before treatment, during the
ﬁrst two weeks and up to 6 months of combination therapy to identify drug
induced changes in correlations between biomarkers (“qgraph” package42 in
R 3.243), while avoiding the confound of multiple comparisons. This focused
attention on Tie2, the time-courses of which were then clustered and compared
with other biomarker data based on the same clusters to determine the origin of the
Tie2 signal. The PFS of the two Tie2-deﬁned clusters of patients were compared.
Having demonstrated the vascular origin of the Tie2 signal, we examined the
prognostic signiﬁcance of each biomarker in a Cox proportional hazard model with
appropriate tests for proportionality and non-linearity. The identiﬁed biomarkers
deﬁned a cohort of patients with signiﬁcantly poor prognosis. Tumor volumetric
and Tie2 trajectories of these patients during treatment were examined. The
trajectories of biomarkers were modeled using Bayesian methods to determine an
inﬂection point where a biomarker’s behavior changed during treatment. This was
then used to determine when biomarker progression occurred and then to evaluate
the additive value of modeling the epithelial and vascular compartments together
with respect to progressive disease.
Network analysis of circulating and imaging biomarkers. The circulating bio-
markers investigated in this study were associated wth angiogenesis biology, epi-
thelial cell death or were conventional clinical tests for tumor burden (platelet
count, LDH and CEA). MRI biomarkers were derived from individual tumor
lesions as described above. One index lesion was followed per patient. We gen-
erated network representations of the correlations between biomarkers, based on:
(i) pre-treatment data, (ii) the ﬁrst two weeks following single agent bevacizumab
administration, (iii) and up to six months treatment with bevacizumab and cyto-
toxic chemotherapy. Matched data enabled correlations between circulating and
imaging biomarkers to be evaluated for the pre-treatment data and the data derived
from the ﬁrst two weeks of combination therapy. Changes in circulating and
imaging biomarkers were assessed after two weeks of treatment. The network
representations minimize the risks of a multiple comparisons analysis, which might
result in insufﬁcient statistical power, and allow interpretation based on existing
knowledge of disease biology.
Clustering patients according to changes in Tie2. The correlation analysis
focused attention on Tie2 and we therefore used an unsupervised hierarchical
clustering method (based on correlation) to explore maximal separation between
Tie2 trajectories. The unsupervised nature of the cluster analysis meant that no
predeﬁned thresholds were used. These two groups of Tie2-deﬁned patients were
characterized by investigating their (1) association with clinical factors pre-
treatment using chi-square test; (2) difference in biomarker levels pre-treatment;
(3) difference in trajectories of circulating biomarkers during treatment; and
(4) difference in trajectories of imaging and epithelial biomarkers to understand
the biological relevance of Tie2.
Investigating prognostic signiﬁcance of biomarkers. The relationships
between clinical factors and biomarkers were assessed by correlation (for
continuous variables) or chi-squared tests (for categorical variables). The prog-
nostic signiﬁcance of each candidate biomarker was assessed by including the
biomarker either as a continuous variable or through dichotomized analysis based
on the distribution median as a sole covariate in a proportional hazards model for
progression. In each case, we tested for the corresponding null hypothesis of no
effect via a Wald test44. Assumption of proportionality was veriﬁed based on
Schoenfeld residuals45. A plot of the Martingale residuals46 from each marker
speciﬁc analysis was examined for evidence of nonlinearity in the
biomarker–hazard relationship. The covariate was subjected to appropriate trans-
formation/categorization, such as log2 transformation, if the above assumptions
were found violated. Biomarkers with univariate p-values that were less than 0.05
were selected for subsequent multivariate analysis, where a backward stepwise
method was applied to identify the subset of biomarkers that best explained sur-
vival. Interactions of selected biomarkers were explored based on biologically
driven hypotheses.
To prevent the estimate from being unduly inﬂuenced by a few patients with
extreme biomarker measurements, derived models were validated using a bootstrap
resampling method. The method makes a more realistic estimation of the
distribution of a variable by random sampling of the data with replacements47.
For each model, 1000 bootstrap samples were generated and the relative
frequency of signiﬁcance for a candidate biomarker was recorded. Biomarkers
retained in the optimum model had to have a relative frequency exceeding 66%
(signiﬁcant in at least two cases out of three); a typical threshold used in bootstrap
analysis.
The analysis described here were carried out following the REMARK48
guidelines.
Clinical signiﬁcance of patterns in Tie2 trajectories. The clustering analysis of
Tie2 trajectories identiﬁed patterns of Tie2 that were associated with worse PFS.
Independently Cox proportional hazard analysis identiﬁed biomarkers whose pre-
treatment values associated with worse PFS. Cut-offs were not pre-deﬁned to avoid
data overﬁtting and multiple comparisons. As a result, the patient cohorts with
worse PFS from the two analyses were different. A chi-squared test was applied to
investigate whether the two analyses identiﬁed a consistent group of patients with
worse PFS.
Dynamics of circulating biomarkers during treatment. Time-dependent changes
in concentrations of each circulating biomarker, measured as log2 ratios to pre-
treatment concentrations, were plotted against time elapsed or the percentage time
that elapsed between the date of treatment start and the date of progression/
censoring (%PFS; time elapsed divided by PFS). The concept of percentage time
was designed to address variation in patient survival12. Missing data were inter-
polated for graphical representation but were not used in any other part of the
analysis.
Modeling biomarker trajectories. Trajectories of selected biomarkers were
modeled using a Bayesian hierarchical modeling approach from actual rather than
interpolated data12. In brief, changes in biomarker concentrations were approxi-
mated to have a piecewise-linear relationship with treatment time where an
inﬂection point separated the decreasing part of the biomarker trajectory from the
subsequent increasing component. The inﬂection point, from a clinical perspective,
was hypothesized to reﬂect a change in tumor behavior and therefore as the earliest
sign of tumor progression12. This Bayesian modeling approach allowed estimation
of the time point at which tumor behavior changes for an individual patient and for
the cohort. It also provided natural tolerance to missing data points. This is further
described below
Deﬁning rules for vascular response and progression. For each biomarker, 95%
conﬁdence intervals of its intra-patient variation were calculated by ﬁtting a
Normal distribution to the variation, calculated from the two pre-treatment sam-
ples. Here, a vascular response was deemed to have occurred when the reduction in
the putative response biomarker exceeded the 95% CI within three cycles of
treatment. Vascular progression was considered to have occurred if elevation of a
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biomarker exceeded a designated cut-off from its recorded nadir point
during treatment. The optimum cut-off was determined using the developed
Bayesian model via inference of pseudo-trials. Full detail on model
development and data inference can be found below. The potential of selected
biomarkers to predict tumor progression was evaluated based on the rules
described above and we then calculated the percentage of patients whose
progressive disease was correctly predicted and the time of that prediction. The
evaluation was performed (1) by using actual biomarker data and (2) by using
data that simulated missing data points from the Bayesian model. The
performance of different biomarkers was compared to explore their biological
roles in tumor progression.
Characterizing biomarker trajectories during treatment. In this study, we
applied a Bayesian hierarchical modeling approach to investigate
concentrations of a speciﬁc biomarker as a function of treatment time. The
approach was applied to develop probability models that deﬁne joint
probability distribution for all observed and unobserved data49. This approach
was especially suitable for analyzing biomarker data as we present in this study
because of its ﬂexibility to produce complicated models with multiple
conceptual layers and large numbers of parameters, as well as its natural
framework to tolerate missing data points which occur frequently in clinical trials.
A similar modeling approach was applied in our previous study investigating
biomarker data from ovarian cancer patients12, in recent literature for
modeling trajectories of PSA in prostate cancer50 and multivariate clinical
factors in Parkinson’s disease51.
The Bayesian hierarchical model, once developed, enabled us to address two
questions. Firstly, it provided a quantitative framework to deﬁne the dynamics
of biomarker concentrations over time. It allowed justiﬁcation of our
hypothesis on inﬂection point, i.e., an inﬂection point separates the decreasing
part of biomarker trajectory from the subsequent increasing part and the
inﬂection point can be considered as a sign of changing tumor behavior.
Secondly, the model enabled inference of the concentration of a biomarker,
on any patient and at any time point during treatment. This meant that we
could carry out pseudo-trials on the same cohort of patients but on different
sample collection schemes. This inference process was different from the
concept of prediction, as it did not generate data for a new patient based on
an existing patient. Instead such estimation resembles interpolating values for
missing data points utilizing information from individual patients and the
whole population. Pseudo-trial data can be used to determine optimum rules
for biomarkers to predict tumor progression, which will be described in detail
below.
Bayesian model and Markov Chain Monte Carlo modeling. The Bayesian
hierarchical model was set up based on a piecewise linear relationship between
biomarker quantity (concentration for circulating biomarkers; various units for
imaging biomarkers) and treatment time (t), parameterized as follows:
Cbiomarker tð Þ ¼ αþ S tinflection  tð Þβt
þS t  tinflectionð Þ βtinflection þ γ t  tinflectionð Þð Þ þ ε
ð1Þ
where C represents the quantity of the biomarker being modeled, α is
the pre-treatment concentration of the biomarker, tinﬂection is the inﬂection
point of biomarker trajectory, β is the slope before the inﬂection point, γ is
the slope after the inﬂection and ε is a random error. S is an indicator
function where
S xð Þ ¼ 1 if x>0
0 if x  0

ð2Þ
The parameters were assigned the following prior distributions to follow the
structure of a Bayesian hierarchical model:
logðαÞ  N μα; σ2α
 
β  α ´ β1 þ E1 ´ β2
 
β1  N μβ1; σ2β1
 
logðβ2Þ  N μβ2; σ2β2
 
E1  B 1; p1ð Þ
γ  α ´ γ1 þ E2 ´ γ2
 
γ1  N μγ1; σ2γ1
 
logðγ2Þ  N μγ2; σ2γ2
 
E2  B 1; p2ð Þ
ε  C ´N 0; σ2ε
 
tinflection  Uð21;PFS 21Þ
Speciﬁcally, α follows a log normal distribution, β is dependent on α and both β,
γ are modeled to follow a combination of a normal and a log normal distribution
that controlled by E1 and E2 (Bernoulli distributions). The reason for setting β and
γ as above is to accommodate the fact that Tie2 trajectories can be clustered into
two distinct groups (Fig. 3) that have different β and γ values (β1, β2 and γ1, γ2). ε
can be considered as technical variation and is therefore modeled to be dependent
on biomarker quantity. tinﬂection is uniformly distributed between 21 days after
treatment starts and 21 days before diagnosis of progression.
The parameters were assigned appropriate prior distributions in accordance
with the biomarker being modeled. For example, the following prior values were
assigned when Tie2 was modeled:
μα  N 4:3; 1ð Þ
σα  N 0:6; 1ð Þ
μβ  N 2; 1ð Þ
μβ2  N 1:5; 1ð Þ
σβ  N 1; 1ð Þ
σβ2  N 1; 1ð Þ
p1  U 0:2; 0:7ð Þ
μγ  N 0; 1ð Þ
μγ2  N 1; 1ð Þ
σγ  N 2; 1ð Þ
σγ2  N 1; 1ð Þ
p2  U 0:2; 0:7ð Þ
σε  N 0:15; 10ð Þ
All biomarkers being modeled were transformed to control their dynamic
ranges. For example, M65 was squared and then multiplied by 10. Ang2 was log2
transformed, and its product with Tie2 was further divided by 1000.
The posterior distributions of the parameters were determined using an Markov
Chain Monte Carlo (MCMC) approach as implemented in Winbugs 1.4. For each
model, three Markov chains were trained at a same time to ensure best coverage.
Table 4 Multivariate analysis of biomarkers before treatment
Hazard ratio (95% CI) p-value Bootstrap (frequency of p < 0.05)
Performance status 1 1.50 (0.89–2.54) 0.13 35.9%
Performance status 2 4.96 (1.42–17.41) 0.012 67.3%
Total tumor volumea 1.10 (1.05–1.16) 0.0003 79.7%
VEGFR2:Ktrans b 1.01 (1.00–1.02) 0.0008 96.3%
Biomarkers with univariate p-values < 0.05 (Table 3) were included in the subsequent multi-variate analysis. The results from multivariate analysis were validated using a bootstrap resampling method,
which examines the stability of the ﬁndings through removal of different data points with re-evaluation of the remaining data. In the multivariate analysis all HRs exceeded 1.00 inferring that the higher
the parameter/biomarker, the worse the outcome
VEGFA and VEGFR2 were correlated circulating biomarkers but given the relationship between VEGFA and Ktrans, it was biologically more plausible that the signal reﬂects VEGFR2. To allow comparisons
of more than one biomarker with PFS, VEGFR2, and Ktrans were analyzed as a ratio (VEGFR2:Ktrans)
atotal tumor volume/100 calculated from CT scan
bVEGFR2/Ktrans WTV and ETV calculated from MRI scan
VEGFA and R2 vascular endothelial growth factor A and receptor 2, HR hazard ratio, Ktrans endothelial transfer constant, PFS progression-free survival, CI conﬁdence interval, MRI magnetic resonance
imaging, CT computerized tomography scan
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They were updated for 50,000 iterations or until sufﬁcient evidence of model
convergence was observed, whichever occurred later. A converged model will be
updated for a further 100,000 iterations to estimate posterior distribution of each
model parameter. According to our observations, convergence was achieved
typically within 20,000 update iterations.
Bayesian hierarchical model generates pseudo-trial data. The Bayesian
hierarchical models parameterized biomarker trajectories during treatment for
each individual patient by means of posterior probability distribution,
considering the observed biomarker data as a random sample from these
distributions. Naturally it allowed “pseudo-trial” data to be generated via
Bayesian predictive inference, which represented the model’s best guess of
biomarker concentration for a speciﬁc patient at a given time, as if the trial
were repeated on the same patients and data were collected based on new
collection scheme. It should be noted that the prediction process did not create new
pseudo-patients, instead it resembles interpolation of values of missing data points.
Predicting tumor progression based on modeled inferred data. We intended to
develop rules on how to use the selected biomarkers in clinic, that is, how to
provide early predictions of tumor progression by monitoring the biomarkers
sequentially during treatment. Based on the inﬂection point hypothesis that was
described above, we designed a generic rule that prediction on tumor progression
was considered if elevation of a biomarker with respect to its recorded nadir point
exceeds a designated alarm threshold. The optimal threshold can be determined
using the following steps:
(1) For any threshold we generated pseudo-trial data for a given biomarker via
prediction from the Bayesian model at a designated time. In this study a
monthly sample collection interval (30 ± 5 days) was applied.
(2) For each patient, we examined the recorded data sequentially following
treatment time. For any given time point, we calculated the percentage
change of biomarker concentration against the nadir concentration recorded
prior to this time point. If the percentage change was larger than the
designated threshold value a prediction of tumor progression was considered
to take place at that time point.
(3) We repeated steps 1–2 ﬁve thousand times.
(4) Biomarker prediction performance was evaluated by summarizing all the
recorded prediction times.
The threshold that predicts disease progression for as many patients as possible,
at a time reasonably close to the genuine date of progression was considered as the
optimum threshold (Table 4).
Data availability
Data generated in this study are available in the Mendeley repository https://doi.
org/10.17632/xcsbspcghg.2.
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